Addex reports limited cash as half-year loss reaches CHF3.46 million
Addex Therapeutics ($ADXN) reported a first-half net loss of CHF3.46 million, compared with CHF3.31 million a year earlier. Its operating loss narrowed to CHF1.13 million, but the share of losses from associates increased to CHF2.33 million. Cash at the half-year end was CHF767,000, down from CHF2.30 million twelve months earlier. The biotech also detailed $2.8 million of gross share-sale proceeds raised after the reporting period, providing additional resources for development. That financing s
0